Be a helping hand to those who need of blood

by Saurashtra Medical & Educational Charitable Trust
Play Video
Be a helping hand to those who need of blood
Be a helping hand to those who need of blood
Be a helping hand to those who need of blood

Life Blood Centre provided blood to patients during outbreak of global pandemic.

  •  Acting as Corona Warriors, Life Blood Centre is working 24 x 7 since inception and during the pandemic period more than 14,000 blood units and around 600 Covid-19 Convalescent Plasma (CCP) have been distributed among Covid-19 patients.

 Total 2929 units of whole blood and various blood products have been issued among 1250 patients in complete lockdown period.

  • Maximum blood products supplied…
  • To treat anaemia (34.14%)
  • Thalassaemia major patients (13.45%)
  • Cancer patients (7.78%)
  • Patients of cardiac surgeries (4.68%)

Activities to support Thalassaemia children

  • 285 thalassaemia major patients are registered with Life Blood Centre.
  • Remain connected and provided mental support through out the Covid-19 pandemic time.
  • Managed to support all patients in terms of fresh blood units supply for transfusion.
  • Uninterrupted Blood Supply: Supported in Covid-19 pandemic time including rare blood groups like “O” Negative, “AB” Negative.
  • Five thalassaemia major patients were infected from Covid-19. Counseled them all and supported them. All fought against Corona virus and recovered.

Attachments: Share on Twitter Share on Facebook


This year, World Blood Donor Day is once again celebrated around the world on 14 June.

The aim is to raise global awareness of the need for safe blood and blood products for transfusion and of the critical contribution voluntary, unpaid blood donors make to national health systems.

Safe blood and blood products and their transfusion are a critical aspect of care and public health. They save millions of lives and improve the health and quality of life of many patients every day. The need for blood is universal, but access to blood for all those who need it is not. Blood shortages are particularly acute in developing countries.

To ensure that everyone who needs safe blood has access to it, all countries need voluntary, unpaid donors who give blood regularly. Throughout the COVID-19 pandemic, despite limited mobility and other challenges, blood donors in many countries have continued to donate blood and plasma to patients who need transfusion. This extraordinary effort during a time of unprecedented crisis highlights the crucial role of well-organized, committed voluntary, non-remunerated blood donors in ensuring a safe and sufficient blood supply during normal and emergency times.

For 2021, the World Blood Donor Day slogan is “Give blood and keep the world beating”.

The message highlights the essential contribution blood donors make to keeping the world pulsating by saving lives and improving others’ health. It reinforces the global call for more people all over the world to donate blood regularly and contribute to better health.

A special focus of this year’s campaign is the role of young people in ensuring a safe blood supply. In many countries, young people have been at the forefront of activities and initiatives aimed at achieving safe blood supplies through voluntary, non-remunerated blood donations. Young people form a large sector of the population in many societies and are generally full of idealism, enthusiasm and creativity.

Due to the current situation of Covid-19 pandemic, we have not organized any mega event at Life Blood Centre.

Keeping theme of world blood donor day in mind, we have decided to felicitate our regular whole blood donors, female donors, SDP donors, Covid-19 Convalescent Plasma donor and blood donation camp organizers who helped us in previous year.

More than 200 blood donors contacted on call.

More than 800 messages sent to blood donors.

Team-LBC managed to collect 118 blood units in a day.

A special token of appreciation along with a special certificate was given to all in-house voluntary blood donors.

Attachments: Share on Twitter Share on Facebook
Excellence Certificate awarded by ISBT, Amsterdam
Excellence Certificate awarded by ISBT, Amsterdam

It is our privilege to inform that Life Blood Centre, Rajkot, Gujarat, India has been awarded by International Society of Blood Transfusion (ISBT), Amsterdam “ISBT Award for Developing Countries 2020” on December 12, 2020.

The ISBT Award for Developing Country was initiated from 2012. The award is presented every two years to only one blood centre across the globe. It is awarded to blood centre from a Developing Country that has made a significant contribution in strengthening Blood Transfusion Practice within the country. This year due to pandemic international congress was organized virtually from December 12-16, 2020 at Amsterdam. Nearly 1700 delegates participated in the congress and professionals from over 100 countries had share their significant contribution.

Life Blood Centre is the only standalone blood bank from India to be honored with this prestigious award. Copy of excellence certificate is attached along with work of Life Blood Centre acknowledged by Professor Erica Wood - President of ISBT, Amsterdam for your kind reference.

Moreover, in year 2010, 2011 and 2019 Life Blood Centre was recognized at International conferences and received Harold Gunson Fellowship Award from ISBT and in 2020 our application on “Threat of dengue to blood safety in dengue-endemic region” was accepted in the innovative initiative of ISBT named “I TRY IT 2020”.

LBC work narrated by ISBT-President
LBC work narrated by ISBT-President
Share on Twitter Share on Facebook

Life Blood Centre (formerly known as Rajkot Voluntary Blood Bank & Research Centre) was established on 06th December 1981. It was the first blood bank in the entire Saurashtra region of Gujarat state. We remain firmly committed to contribute beyond blood banking by the whole process of voluntary blood collection, testing, storage, distribution of scientifically safe blood and provide vital information on blood transfusion at multi-specialty Hospitals, private Doctors, para medical staffs by providing training and by preparing various brochure and leaflets on define topics. Today, Life Blood Centre (LBC) is considered as one of the most reliable blood banks, having touched hundreds of thousands of lives.

Attachments: Share on Twitter Share on Facebook
X - Ray Irradiator - First in Asia Pacific
X - Ray Irradiator - First in Asia Pacific


TA-GvHD (Transfusion Associated Graft versus Host Disease) is a very rare but usually fatal complication following transfusion of lymphocyte-containing blood components. Although the first reports concerned cases where viable allogeneic lymphocytes had been transfused into immunosuppressed recipients, it became apparent that non-immunosuppressed patients could also experience this problem, particularly if the blood components they received came from an HLA haploidentical unrelated donor or family member.

The risk associated with an individual transfusion depends on the number and viability of contaminating lymphocytes, susceptibility of the recipient’s immune system to their engraftment and degree of immunological (HLA) disparity between donor and patient. The minimum number of transfused lymphocytes necessary to provoke a GvHD reaction is unknown and may vary by clinical settings. Until recently, gamma irradiation of cellular blood components has been the mainstay of TA-GvHD prevention but now X-Ray IRRADIATION cellular blood products are getting into practice.

Fortunately, first installation of X-Ray irradiator of South-East Asia is done in Rajkot at Life Blood Centre.

Pathogenesis, clinical features and diagnosis of TA-GvHD


TA-GvHD is a potential complication of transfusion of any blood component containing viable T lymphocytes when there is disparity in the histocompatibility antigens between donor and recipient. As well as the classical skin, gut and liver involvement seen in GvHD occurring after allogeneic stem cell transplantation, TA-GvHD is characterized by profound marrow hypoplasia and mortality in excess of 90%. There is a particular risk of TA-GvHD when the donor and patient share an HLA haplotype, as occurs within families, or in populations with restricted haplotype diversity In the Japanese population, the incidence of TA-GvHD is 10–20 times higher than in the North American Caucasian population. 

Clinical features:

The early features are fever, maculopapular skin rash, diarrhoea and hepatitis occurring 1–2 weeks after transfusion. Bone marrow involvement produces severe hypoplasia with profound pancytopenia.


Diagnosis is usually made by biopsy of skin, gut or liver supported by evidence of persistence of donor lymphocytes. The presence of cells of donor origin may be demonstrated by polymerase chain reaction in peripheral blood (Utter et. al., 2007) or short tandem repeat analysis using peripheral blood and skin biopsies from affected and non-affected sites in the patient, and peripheral blood samples from the implicated donors. 

Prevention of TA-GVHD 


The major technology for preventing TA-GvHD is irradiation of blood components to inactivate residual lymphocytes Gamma rays and X-rays are similar in their ability to inactivate T lymphocytes in blood components at a given absorbed dose. Gamma-irradiators are expensive and eventual decommissioning and disposal present significant difficulties These highly radioactive cores may present a security risk in hospital settings. As the source decays, regular recalibration is required and irradiation time progressively increases. Dedicated X-ray blood irradiators are now available, have been widely used in North Americaand are being introduced by the UK Transfusion Services. X-ray irradiation machines are less expensive and the absence of a radioactive source results in fewer regulatory requirements. Published data indicate that the small differences in red cell permeability found between X- and gamma- irradiated components are not clinically significant. Further work, commissioned by the Joint Professional Advisory Committee of the UK Transfusion Services on blood components irradiated using the Raycell X-irradiator, concluded that gamma and X-irradiation can be regarded as equivalent and both are suitable and safe for clinical use. 

Effective dose:

Studies using sensitive-limiting dilution assays indicate that a dose of 25 Gy, measured at the mid-plane of a component, completely abolishes mixed lymphocyte response. 

The American Association of Blood Banks (AABB) recommends a dose of 25 Gy to the central area of the component with no portion receiving <15 Gy (AABB 2006). The Japanese Society of Blood Transfusion’s Guidelines recommend a similar dose. In the UK, a minimum of 25 Gy is recommended, but with the dose to any bag in the container not exceeding 50 Gy. To ensure this dose distribution is achieved, consultation with supporting physicists is mandatory. 

Blood components that should be irradiated 

Lymphocyte viability is retained in stored red cells for at least 3 weeks and TA-GvHD has been reported after transfusion of whole blood, red cells, platelets and granulocytes .TA-GvHD has not been described following transfusion of frozen deglycerolized red cells, which are thoroughly washed free of leucocytes after thawing. 

TA-GvHD has not been described following transfusion of cryoprecipitate, fresh frozen plasma or fractionated plasma products, such as clotting factor concentrates, albumin and intravenous immunoglobulin 

Donations from family members and HLA-selected donors.....

Because of the sharing of HLA haplotypes, donations from 

Family members pose a particular risk of TA-GvHD. Red cells, granulocytes, platelets and fresh plasma have all been implicated in TA-GvHD after transfusion from family members (Agbaht et. al.,2007), and there is an increased risk with donations from both first and second-degree relatives. 

Several cases of TA-GvHD have been reported from Japan, where limited diversity of HLA haplotypes in the population increases the chance of a transfusion recipient receiving blood from a HLA haploidentical or HLA-identical donor. These observations are of relevance for patients receiving HLA-selected platelet concentrates from non-family members because of alloimmune refractoriness to random donor platelets. This would be expected to increase the risk of TA-GvHD, especially if the platelet donor is homozygous for one of the recipient HLA-haplotypes (analogous to donations within families or within racial groups of limited genetic diversity). A case of TA-GvHD in an immunocompetent recipient following transfusion of blood components from an unrelated HLA homozygous donor was recently reported , and four more cases were reported from Turkey in immunocompetent recipients who had received non-irradiated blood from relatives. The risk from HLA-selected platelets where the donor is not homozygous is uncertain. However, many transfusion centres now specifically maintain panels of homozygous donors for refractory patients, and in practice it is probably more reliable to recommend irradiation of all HLA-selected platelets, rather than risk the misallocation of some donations 

Red cells....

Red cells can be irradiated up to 14 days after collection and stored for at least a further 14 days without significant loss of viability. Irradiation may result in reduced post-transfusion red cell recovery after more prolonged storage, although recovery is still above the minimum acceptable 75%. Irradiation of red cells results in accelerated leakage of potassium and an increase in the level of extracellular potassium. 'Top-up’ transfusions given at standard flow rates do not constitute a risk of hyperkaliemia, even when given to premature neonates. Potassium load may be clinically important in rapid large-volume transfusions, such as neonatal exchange transfusion or intrauterine trans- fusion. Routine removal of supernatant plasma and washing of irradiated red cells is not considered necessary but, if this procedure is undertaken, the washed cells should be transfused as soon as possible, ideally within 3 to 4 hours. 

Free haemoglobin levels are increased in stored irradiated red cell components,but remain within acceptable limits. Irradiation has no clinically significant effect on red cell pH, glucose consumption, ATP or 2,3 DPG levels.


Irradiation below 50 Gy has not been shown to produce significant clinical changes in platelet function.


The evidence for irradiation damage to granulocyte function is conflicting, but in any case granulocyte products should be transfused as soon as possible after irradiation.


Irradiated components not used for the intended recipient can safely be returned to stock to be used for recipients who do not require irradiated components. The reduction in shelf life must be observed.

 Clinical indications of irradiated blood components.......

(a)   Definite Indications

  • Directed donations ( from blood relatives)
  • HLA-selected/matched platelet transfusions
  • Granulocyte transfusions
  • Intrauterine & all subsequent neonatal exchange transfusions
  • Congenital cellular immunodeficiency disorders
  • Allogeneic and autologus haematopoietic stem cell transplantation
  • Hodgkin lymphoma
  • Patients receiving nucleoside analogues for malignant or non-malignant disorders
  • Patients receiving alemtuzumab for malignant or non-malignant disorders and transplantation

 (b)   Possible Indications

  • Premature infants and infants weighing < 1300 gm
  • All newborn infants
  • Acute leukemia
  • Non-Hodgkin lymphoma
  • Patients with B cell malignancy who receive non-nucleoside analogue containing chemotherapy and/or radiotherapy leading to lymphopenia < 0.5x109/L
  • T cell malignancies
  • Patients receiving high doses of chemotherapy and/or irradiation sufficient to cause lymphopenia < 0.5x 109/L
  • Patients receiving long term or high dose steroids as therapy for malignancies
  • Aplastic anaemia receiving immunosuppressive therapy
  • Massive transfusion for trauma

 (c)    No Indications

  • Congenital humoral deficiency disorders
  • Solid organ transplantation
  • Small volume transfusion to neonates
Advantages of X-Ray Irradiated Blood
Advantages of X-Ray Irradiated Blood
Share on Twitter Share on Facebook

About Project Reports

Project Reports on GlobalGiving are posted directly to by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.

If you donate to this project or have donated to this project, you will get an e-mail when this project posts a report. You can also subscribe for reports via e-mail without donating.

Get Reports via Email

We'll only email you new reports and updates about this project.

Organization Information

Saurashtra Medical & Educational Charitable Trust

Location: Rajkot, GUJARAT - India
Facebook: Facebook Page
Twitter: @liferajkot
Project Leader:
Rushikesh Pandya
Project Life
Rajkot, GUJARAT India
$7,059 raised of $35,000 goal
54 donations
$27,941 to go
Donate Now
Important: GlobalGiving is currently unable to disburse funds to this project. Please note that this is due to restrictions on GlobalGiving’s ability to disburse to Indian-banked organizations and not a reflection on this project. GlobalGiving is one of the many nonprofits on whom these restrictions have been put. Learn more
Donating through GlobalGiving is safe, secure, and easy with many payment options to choose from. View other ways to donate

Saurashtra Medical & Educational Charitable Trust has earned this recognition on GlobalGiving:

Help raise money!

Support this important cause by creating a personalized fundraising page.

Start a Fundraiser

Learn more about GlobalGiving

Teenage Science Students
Vetting +
Due Diligence


Woman Holding a Gift Card
Gift Cards

Young Girl with a Bicycle

Sign up for the GlobalGiving Newsletter

WARNING: Javascript is currently disabled or is not available in your browser. GlobalGiving makes extensive use of Javascript and will not function properly with Javascript disabled. Please enable Javascript and refresh this page.